logo

Lipocine Inc (LPCN)



Trade LPCN now with
  Date
  Headline
3/10/2023 8:41:04 AM Lipocine FY Net Loss/shr $0.13 Vs, Loss/shr $0.01 Last Year
12/19/2022 8:11:46 AM Lipocine Completes Enrollment Of LPCN 1148 Phase 2 Study For Decompensated Cirrhosis
11/9/2022 8:05:00 AM Lipocine Q3 Loss/shr Narrows To $0.03 From $0.04 Last Year
9/15/2022 8:10:51 AM Lipocine Reports Favorable Regulatory Pathway On Oral LPCN 1154 For Post-Partum Depression; Stock Up
8/8/2022 8:19:17 AM Lipocine Inc. Q2 Net Loss/shr $0.04 Vs. Loss/shr $0.08 Last Year
7/11/2022 8:10:53 AM Lipocine : FDA Clears LPCN 2101 IND For Adult Epilepsy Treatment
7/11/2022 8:00:00 AM FDA Clears LPCN 2101 IND for Adult Epilepsy Treatment (Press Release)
5/9/2022 8:16:03 AM Lipocine Q1 Net Loss $3.5 Mln Or $0.04/shr Vs Net Loss Of $3.4 Mln Or $0.04/shr Prior Year
4/11/2022 8:00:00 AM LIPOCINE ANNOUNCES BOARD of DIRECTOR APPOINTMENTS (Press Release)
3/29/2022 7:13:39 AM Lipocine: FDA Approves TLANDO As Oral Testosterone Replacement Therapy In Adult Males For Hypogonadism
3/1/2022 8:10:44 AM Lipocine Reports Regulatory Guidance On LPCN 1144 In Non-cirrhotic NASH
2/3/2022 8:22:58 AM Lipocine Says Its Partner Received FDA Acceptance Of NDA Resubmission For Tlando